Antengene has secured the money under series B financing round led by Boyu Capital and FountainVest. The participants include new investors such as Celgene, WuXi Corporate Venture Fund
CellforCure is a major French contract development and manufacturing organization engaged in the production of cell and gene therapies in Europe. As per terms of the deal, Novartis
Under the terms of the agreement, Agenus will receive $150m upon closing, which includes a $120m upfront cash payment and a $30m equity investment. The agreement also includes
The new facility, which is strategically located in close vicinity to the Ljubljana Airport, will carry out the distribution of finished products worldwide and will be used for
UPSA is a French pharmaceutical manufacturer, which develops and produces pharmaceutical drugs and supplements for everyday ailments. The company provides various products in therapeutic areas, including pain, cough
Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) indicated to treat patients who use hemodialysis or peritoneal dialysis. It will help induce coordinated erythropoiesis, increase red blood
MP0310 is a preclinical molecule designed to locally activate immune cells in the tumor by binding to FAP on tumor stromal cells (localizer) and co-stimulating T cells via
VE303 is claimed to be the first drug featuring a rationally-defined bacterial consortium to advance to phase 2 study. The earlier announced phase 1a/1b study showed rapid, durable,
Alvotech and Fuji Pharma recently announced an exclusive agreement for development and commercialization of biosimilars in Japan. Fuji´s investment into Alvotech further strengthens the partnership between the companies
Zirabev is a monoclonal antibody for the treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer, unresectable advanced, metastatic or recurrent non-small cell lung cancer
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.